Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands

TEVA PHARMACEUTICAL INDUSTRIES LTD

Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).
Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% YoY LC to >$1B; 2026 revenue outlook raised to ~$3.7B combined.
Acquired Emalex for ~$700M cash; NDA for ecopipam (Tourette) submitted; $726M expenses in Q2.
Generics revenues down 15% YoY LC due to lenalidomide competition; biosimilars on track for $800M by 2027.
ADS program replaced with ordinary shares on NYSE starting Sept 14, 2026; Fitch upgraded to BBB-.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.